Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013012628 - IMMUNE-STIMULATING PHOTOACTIVE HYBRID NANOPARTICLES

Publication Number WO/2013/012628
Publication Date 24.01.2013
International Application No. PCT/US2012/046171
International Filing Date 11.07.2012
IPC
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 9/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
A61K 9/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
A61K 47/30 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 41/0071
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation ; ; Therapies using these preparations
0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US]/[US] (AllExceptUS)
  • DHAR, Shanta [IN]/[US] (UsOnly)
  • CHOI, Joshua [US]/[US] (UsOnly)
  • MARRACHE, Sean (UsOnly)
Inventors
  • DHAR, Shanta
  • CHOI, Joshua
  • MARRACHE, Sean
Agents
  • HAYZER, David, J.
Priority Data
61/508,24215.07.2011US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNE-STIMULATING PHOTOACTIVE HYBRID NANOPARTICLES
(FR) NANOPARTICULES HYBRIDES PHOTOACTIVES IMMUNOSTIMULANTES
Abstract
(EN)
Provides is a therapeutic technology that combines the phototoxic and immune- stimulating ability of photodynamic therapy with the widespread effectiveness of the immune system to reduce the viability of such as cancer cells and tumors. The nanoparticle compositions of the disclosure combine an immunostimulant with a photosensitizer using a nanoparticle delivery platform. For example, zinc pthalocyanine, which is a long-wavelength absorbing photosensitizer, integrated into a polymeric nanoparticle core made up of poly(D, L-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG). The outside surface of the core can be coated with metallic nanoparticles, which are then modified with CpG- ODN. Metastatic mouse breast carcinoma cells showed significant photocytotoxicity of the hybrid after irradiation with a 660 nm LASER light and this activity was remarkably better than either treatment alone. Treatment of mouse bone marrow derived dendritic cells with the photodynamic therapy-killed 4T1 cell lysate showed that the combination of photodynamic therapy with a synerg istic immunostimulant in a single nanoparticle system resulted in an immune response suitable for the treatment of such as a metastatic cancer.
(FR)
La présente invention concerne une technique thérapeutique qui combine la capacité phototoxique et immunostimulante d'un traitement photodynamique avec l'efficacité généralisée du système immunitaire pour réduire la viabilité des cellules cancéreuses et des tumeurs. Les compositions de nanoparticules de l'invention combinent un immunostimulant avec un photosensibilisateur au moyen d'une plate-forme d'administration de nanoparticules. Par exemple, de la phtalocyanine de zinc, qui est un photosensibilisateur absorbant les longueurs d'onde longues, est intégrée dans un noyau nanoparticulaire polymère constitué de poly(acide D,L-lactique-co-acide glycolique)-b-poly(éthylène glycol) (PLGA-b-PEG). La surface externe du noyau peut être revêtue avec des nanoparticules métalliques qui sont ensuite modifiées avec du CpG-ODN. Un photocytotoxicité importante de l'hybride est observée sur des cellules de carcinome mammaire murin métastatique après irradiation avec une lumière laser de 660 nm, et cette activité est bien meilleure qu'avec l'un ou l'autre traitement seul. Le traitement de cellules dendritiques dérivées d'une moelle osseuse de souris avec le traitement photodynamique-lysat de cellules 4T1 tuées montre que la combinaison du traitement photodynamique avec un immunostimulant synergique dans un unique système nanoparticulaire produit une réponse immunitaire appropriée pour le traitement d'un tel cancer métastatique.
Also published as
Latest bibliographic data on file with the International Bureau